Know Cancer

or
forgot password

Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase II Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology)


Phase 2
41 Years
N/A
Open (Enrolling)
Female
Breast Cancer, Carcinoma in Situ of the Breast

Thank you

Trial Information

Hypofractionated Versus Standard Fractionated Whole Breast Irradiation to Node-negative Breast Cancer Patients: a Randomized Phase II Trial, CIRRO (The Lundbeck Foundation Center for International Research in Radiation Oncology)


The randomization is between 50 Gy/25 fractions, 2.0 Gy per fraction, 5 fractions weekly,
and 40 Gy/15 fractions, 2.67 Gy per fraction, 5 fractions weekly. The primary endpoint is
late radiation morbidity; secondly, we want to investigate the frequency of local
recurrences, and try to establish a genetic risk profile for development of late radiation
morbidity.

The hypothesis is that women operated with breast conserving strategy for early breast
cancer can be offered moderately hypofractionated radiotherapy without developing more late
radiation morbidity compared to standard fractionated radiotherapy.


Inclusion Criteria:



- operated with breast conserving strategy for:

1. invasive breast cancer, pT1-2, pN0-1mi, M0 OR

2. carcinoma in situ of the breast

Exclusion Criteria:

- previous radiation of the breast/thorax

- breast implants

- pregnant/lactating

- comorbidity which may hinder the patient in completing the therapy and complete
follow up for 10 years

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Grade 2 or 3 fibrosis 3 years after radiotherapy

Outcome Time Frame:

3 years

Safety Issue:

Yes

Principal Investigator

Lars Stenbygaard, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Aalborg Universityhospital

Authority:

Denmark: Ethics Committee

Study ID:

DBCG hypo protocol

NCT ID:

NCT00909818

Start Date:

May 2009

Completion Date:

May 2022

Related Keywords:

  • Breast Cancer
  • Carcinoma in Situ of the Breast
  • Breast Neoplasms
  • Carcinoma
  • Carcinoma in Situ

Name

Location